These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 38533153)
1. The Safety Profile of Common COVID-19 Vaccines in Patients With Multiple Sclerosis. Aladdin YS; Alqarni DA; Alamoudi SW; Alharbi AA; Fudhah WA; Alghamdi G; Attar A Cureus; 2024 Feb; 16(2):e54852. PubMed ID: 38533153 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccination in people with multiple sclerosis, real-life experience. Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255 [TBL] [Abstract][Full Text] [Related]
3. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090 [TBL] [Abstract][Full Text] [Related]
6. Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study. Aldali J; Meo SA; Al-Khlaiwi T Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851109 [TBL] [Abstract][Full Text] [Related]
7. Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland. Paczkowska A; Hoffmann K; Michalak M; Hans-Wytrychowska A; Bryl W; Kopciuch D; Zaprutko T; Ratajczak P; Nowakowska E; Kus K Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335066 [TBL] [Abstract][Full Text] [Related]
8. BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees. Alghamdi AN; Alotaibi MI; Alqahtani AS; Al Aboud D; Abdel-Moneim AS Front Med (Lausanne); 2021; 8():760047. PubMed ID: 34692740 [No Abstract] [Full Text] [Related]
9. Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study. Sharif N; Opu RR; Saha T; Khan A; Aljohani A; Alsuwat MA; García CO; Vázquez AA; Alzahrani KJ; Miramontes-González JP; Dey SK Sci Rep; 2024 Oct; 14(1):23794. PubMed ID: 39394252 [TBL] [Abstract][Full Text] [Related]
10. Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study. Alkhalifah JM; Al Seraihi A; Al-Tawfiq JA; Alshehri BF; Alhaluli AH; Alsulais NM; Alessa MM; Seddiq W; Aljeri T; Qahtani MH; Barry M; Al-Otaiby M Front Public Health; 2023; 11():1043696. PubMed ID: 36908451 [TBL] [Abstract][Full Text] [Related]
11. Analyzing COVID-19 Vaccination Side Effects Among the Adult Population in Jeddah, Saudi Arabia. Alamri T; Anwer F; Butt NS; Alganmi AH; Alotaibi SA; Alzibali KF; Hawsawi HA; Bakarman M; Malik AA Cureus; 2023 Oct; 15(10):e47136. PubMed ID: 37854474 [TBL] [Abstract][Full Text] [Related]
12. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance. Chinnadurai R; Wu HHL; Cox E; Moore J; Clough T; Lamerton E; Donne R; O'Riordan E; Poulikakos D Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455248 [TBL] [Abstract][Full Text] [Related]
13. Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination. Labani A; Chou S; Kaviani K; Ropero B; Russman K; Becker D Mult Scler Relat Disord; 2023 Sep; 77():104865. PubMed ID: 37418929 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. Bouillon K; Baricault B; Botton J; Jabagi MJ; Bertrand M; Semenzato L; Le Vu S; Drouin J; Dray-Spira R; Weill A; Zureik M BMJ Med; 2022; 1(1):e000104. PubMed ID: 36936561 [TBL] [Abstract][Full Text] [Related]
15. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426 [TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
17. Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia. AlRuthia Y; Al-Salloum HF; Almohammed OA; Alqahtani AS; Al-Abdulkarim HA; Alsofayan YM; Almudarra SS; AlQahtani SH; Almutlaq A; Alabdulkareem K; Balkhi B; Almutairi HT; Alanazi AS; Asiri YA Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214781 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort. Nguyen VG; Yavlinsky A; Beale S; Hoskins S; Byrne TE; Lampos V; Braithwaite I; Fong WLE; Fragaszy E; Geismar C; Kovar J; Navaratnam AMD; Patel P; Shrotri M; Weber S; Hayward AC; Aldridge RW Int J Epidemiol; 2023 Apr; 52(2):342-354. PubMed ID: 36655537 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ; Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855 [TBL] [Abstract][Full Text] [Related]
20. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]